600 Demographic characteristics and treatment changes in people with cystic fibrosis in 2019 and 2022: a single-center experience by Emran, J., Yeley, J., Brown, C.

Get full text

172 Treatment changes and outcomes in adults taking elexacaftor/tezacaftor/ivacaftor at two years: A single-center experience by Azeem, Q., Yeley, J., Vogt, H., Powers, C., Brown, C.

Get full text

438 Advanced practice providers in U.S. cystic fibrosis centers: current state of practice by Bichl, S., Brady, C., Dunitz, J., Dykes, S., George, C., Hamilton, J., Willey-Courand, D., Katz, L., Gifford, L., Yeley, J., Brown, R.

Get full text

Genetic Modifiers of Liver Disease in Cystic Fibrosis by Bartlett, Jaclyn R, Friedman, Kenneth J, Ling, Simon C, Pace, Rhonda G, Bell, Scott C, Bourke, Billy, Castaldo, Giuseppe, Castellani, Carlo, Cipolli, Marco, Colombo, Carla, Colombo, John L, Debray, Dominique, Fernandez, Adriana, Lacaille, Florence, Macek, Milan, Rowland, Marion, Salvatore, Francesco, Taylor, Christopher J, Wainwright, Claire, Wilschanski, Michael, Zemková, Dana, Hannah, William B, Phillips, M. James, Corey, Mary, Zielenski, Julian, Dorfman, Ruslan, Wang, Yunfei, Zou, Fei, Silverman, Lawrence M, Drumm, Mitchell L, Wright, Fred A, Lange, Ethan M, Durie, Peter R, Knowles, Michael R, Gene Modifier Study Group, for the

Get full text